Physician profile
William R Downs
NPI 1801833132
$2,930.97
in general payments reported to CMS, 2019-2025
14 companies · $332 in 2025
The $332 reported for 2025 was more than what 90% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $214 · 2021: $717 · 2022: $480 · 2023: $266 · 2024: $254 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,401.67 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $532.77 | 2019-2025 | Airsupra, Andexxa |
| Gilead Sciences, INC. | $183.07 | 2021-2023 | Veklury |
| Abbvie INC. | $155.83 | 2025 | |
| Allergan, INC. | $133.97 | 2020 | |
| Pfizer INC. | $125.76 | 2023-2024 | |
| Boston Scientific Corporation | $123.91 | 2019 | |
| Csl Behring | $104.85 | 2019-2020 | |
| Chiesi USA, INC. | $69.27 | 2023-2025 | Cleviprex |
| Portola Pharmaceuticals, LLC | $27.93 | 2019 | |
| Mindray Ds USA, INC. | $24.98 | 2023 | Te7 Max, Te X |
| Purdue Pharma L.P. | $18.56 | 2025 | Nalmefene Hydrochloride |
| Amgen INC. | $14.86 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.